IL178241A0 - NOVEL 2 - (1 - AZA - BICYCLO [2.2.2] OCT - 3 - YL) - 2, 3 - DIHYDROISOINDOL - 1 - ONE /5, 6 - DIHYDRO - FURO [2, 3 - c] PYRROL - 4 - ONE DERIVATIVES LIGANDS FOR ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR - Google Patents

NOVEL 2 - (1 - AZA - BICYCLO [2.2.2] OCT - 3 - YL) - 2, 3 - DIHYDROISOINDOL - 1 - ONE /5, 6 - DIHYDRO - FURO [2, 3 - c] PYRROL - 4 - ONE DERIVATIVES LIGANDS FOR ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR

Info

Publication number
IL178241A0
IL178241A0 IL178241A IL17824106A IL178241A0 IL 178241 A0 IL178241 A0 IL 178241A0 IL 178241 A IL178241 A IL 178241A IL 17824106 A IL17824106 A IL 17824106A IL 178241 A0 IL178241 A0 IL 178241A0
Authority
IL
Israel
Prior art keywords
dihydroisoindol
furo
pyrrol
aza
bicyclo
Prior art date
Application number
IL178241A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Marc Chapdelaine
Keith J Herzog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Marc Chapdelaine, Keith J Herzog filed Critical Astrazeneca Ab
Publication of IL178241A0 publication Critical patent/IL178241A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL178241A 2004-04-14 2006-09-21 NOVEL 2 - (1 - AZA - BICYCLO [2.2.2] OCT - 3 - YL) - 2, 3 - DIHYDROISOINDOL - 1 - ONE /5, 6 - DIHYDRO - FURO [2, 3 - c] PYRROL - 4 - ONE DERIVATIVES LIGANDS FOR ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR IL178241A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0400970A SE0400970D0 (sv) 2004-04-14 2004-04-14 Nicotinic acetylcholine receptor ligands
PCT/SE2005/000500 WO2005100351A1 (en) 2004-04-14 2005-04-06 NOVEL 2-(1-AZA-BICYCLO[2.2.2]OCT-3-yl)-2,3-DIHYDROISOINDOL-l-ONE/5,6-DIHYDRO-FURO[2,3-c]PYRROL-4ONE DERIVATIVES LIGANDS FOR ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR

Publications (1)

Publication Number Publication Date
IL178241A0 true IL178241A0 (en) 2006-12-31

Family

ID=32294312

Family Applications (1)

Application Number Title Priority Date Filing Date
IL178241A IL178241A0 (en) 2004-04-14 2006-09-21 NOVEL 2 - (1 - AZA - BICYCLO [2.2.2] OCT - 3 - YL) - 2, 3 - DIHYDROISOINDOL - 1 - ONE /5, 6 - DIHYDRO - FURO [2, 3 - c] PYRROL - 4 - ONE DERIVATIVES LIGANDS FOR ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR

Country Status (14)

Country Link
US (1) US7566727B2 (enExample)
EP (1) EP1737854A1 (enExample)
JP (1) JP2007532637A (enExample)
CN (1) CN1968951A (enExample)
AU (1) AU2005233492B2 (enExample)
BR (1) BRPI0509777A (enExample)
CA (1) CA2563010A1 (enExample)
IL (1) IL178241A0 (enExample)
NO (1) NO20065199L (enExample)
RU (2) RU2372350C2 (enExample)
SE (1) SE0400970D0 (enExample)
UA (1) UA86617C2 (enExample)
WO (1) WO2005100351A1 (enExample)
ZA (1) ZA200608412B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807706B2 (en) 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
TW200804281A (en) * 2006-02-16 2008-01-16 Astrazeneca Ab New metabotropic glutamate receptor-potentiating isoindolones
TWI417100B (zh) 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
WO2009042907A1 (en) * 2007-09-27 2009-04-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
US7790760B2 (en) 2008-06-06 2010-09-07 Astrazeneca Ab Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286
US8669259B2 (en) 2009-08-26 2014-03-11 Merck Sharp & Dohme Corp. Heterocyclic amide compounds as protein kinase inhibitors
KR101758046B1 (ko) * 2009-12-22 2017-07-14 버텍스 파마슈티칼스 인코포레이티드 포스파티딜이노시톨 3-키나제의 이소인돌리논 억제제
KR20120125618A (ko) 2009-12-31 2012-11-16 피라말 헬쓰케어 리미티드 디아실글리세롤 아실 전이효소의 억제제
JO3383B1 (ar) * 2013-03-14 2019-03-13 Lilly Co Eli مثبطات cdc7
US10329289B2 (en) 2015-12-23 2019-06-25 Merck Sharp & Dohme Corp. 6,7-dihydro-5H-pyrrolo[3,4-B]pyridin-5-one allosteric modulators of the M4 muscarinic acetylcholine receptor
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
KR20190093205A (ko) 2016-12-21 2019-08-08 바이오테릭스, 인코포레이티드 단백질 표적화에 사용하기 위한 티에노피롤 유도체, 조성물, 방법 및 이의 용도
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
WO2018210229A1 (zh) * 2017-05-18 2018-11-22 南京明德新药研发股份有限公司 α-7尼古丁乙酰胆碱受体激动剂及应用
CN107188900B (zh) * 2017-05-27 2019-09-06 北京师范大学 α7烟碱型乙酰胆碱受体的配体化合物及其应用
WO2018226545A1 (en) * 2017-06-09 2018-12-13 Merck Sharp & Dohme Corp. Azabicyclo[4.1.0]heptane allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2019000238A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000236A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000237A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
NL2021185B1 (en) 2018-06-26 2020-01-06 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Combination Therapy and Use Thereof for Treating Cancer
EP4251149A4 (en) * 2020-11-24 2024-10-30 Merck Sharp & Dohme LLC MODIFIED ISOINDOLINONES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5491148A (en) * 1991-04-26 1996-02-13 Syntex (U.S.A.) Inc. Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists
SE9201478D0 (sv) * 1992-05-11 1992-05-11 Kabi Pharmacia Ab Heteroaromatic quinuclidinenes, their use and preparation
NO2005012I1 (no) * 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
IT1303123B1 (it) * 1998-10-13 2000-10-30 Rotta Research Lab Derivati basici di benz(e)isoindol-1-oni e pirrolo(3,4-c)chinolin-1-oni ad attivita' 5ht3 antagonista, loro preparazione ed
DE10045112A1 (de) 2000-09-11 2002-03-21 Merck Patent Gmbh Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems
ATE385497T1 (de) * 2000-12-01 2008-02-15 Neurosearch As 3-substituierte quinuclidin-derivate und deren verwendung als nikotinischen agonisten
DE10118551A1 (de) * 2001-04-14 2002-10-17 Merck Patent Gmbh Nikotinische Acetylcholinrezeptor Liganden
NZ529880A (en) * 2001-07-06 2005-09-30 Neurosearch As Novel compounds, their preparation and use
EP1532144B1 (en) * 2002-08-14 2008-01-23 Neurosearch A/S quinuclidine derivatives and their use

Also Published As

Publication number Publication date
RU2006135481A (ru) 2008-05-20
US7566727B2 (en) 2009-07-28
SE0400970D0 (sv) 2004-04-14
NO20065199L (no) 2006-11-13
WO2005100351A1 (en) 2005-10-27
RU2372350C2 (ru) 2009-11-10
US20070213342A1 (en) 2007-09-13
CN1968951A (zh) 2007-05-23
BRPI0509777A (pt) 2007-10-23
AU2005233492A1 (en) 2005-10-27
CA2563010A1 (en) 2005-10-27
RU2009126341A (ru) 2011-01-20
AU2005233492B2 (en) 2009-06-11
ZA200608412B (en) 2008-09-25
UA86617C2 (en) 2009-05-12
JP2007532637A (ja) 2007-11-15
EP1737854A1 (en) 2007-01-03

Similar Documents

Publication Publication Date Title
IL178241A0 (en) NOVEL 2 - (1 - AZA - BICYCLO [2.2.2] OCT - 3 - YL) - 2, 3 - DIHYDROISOINDOL - 1 - ONE /5, 6 - DIHYDRO - FURO [2, 3 - c] PYRROL - 4 - ONE DERIVATIVES LIGANDS FOR ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR
IL160896A0 (en) Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
AP2006003566A0 (en) Muscarinic Acetycholine receptor antagonists.
AU2003214936A1 (en) Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
IL172762A0 (en) Spiro [1-azabicyclo [2.2.2]octan-3,5'-oxazolidin]-2'-one derivatives with affinity to the alpha7 nicotinic acetylcholine receptor
DE60038823D1 (de) Diazabicycloderivate als Nikotin-Acetylcholin-Rezeptorliganden
ZA200200232B (en) Quinuclidine derivatives and their use as muscarinic M3 receptor ligands.
IL183568A (en) Process for making 7,8-dihydro-5 h-patridine-6-onh
IL181044A0 (en) Antagonizing interleukin-21 receptor activity
IL183603A0 (en) Nicotinic acetylcholine receptor ligands
IL175993A0 (en) Nicotinic acetylcholine receptor ligands
PT1838683E (pt) Um processo para a preparação de derivados de [1,4,5]-oxadiazepina
MXPA03002076A (es) Derivados de (2-azabiciclo(2.2.1)hept-7-il) metanol como agonistas de receptores nicotinicos de acetilcolina.
ZA200610587B (en) 1-Heterocyclyl-1,5-dihydro-pyrido[3,2-b]indol-2-ones
HK1101636A (en) Novel 2-(1-aza-bicyclo[2.2.2]oct-3-yl)-2,3-dihydroisoindol-l-one/5,6-dihydro-furo[2,3-c]pyrrol-4one derivatives ligands for alpha 7 nicotinic acetylcholine receptor
ZA200702070B (en) Process for preparing substituted 8-azablcyclo[3.2.1] octan-3-ols
IL183598A0 (en) Nicotinic acetylcholine receptor ligands
ZA200701015B (en) Antagonizing interleukin-21 receptor activity
IL176073A0 (en) Nicotinic acetylcholine receptor ligands
DK1784403T3 (da) Pyrrolo[3,2-b]pyridinderivater samt fremgangsmåder til deres fremstilling
IL176071A0 (en) Nicotinic acetylcholine receptor ligands
HK1089162A (en) Spiro [1-azabicyclo [2.2.2]octan-3,5'-oxazolidin-2'-one] derivatives with affinity to the alpha7 nicotinic acetylcholine receptor
ZA200502316B (en) 4-Oxo-4,6,7,8-tetrahydrop-pyrrolofÄ1,2-aÜpyrazine-6-carbox-amide compounds, a process for their preparation and pharmaceutical compositions containingthem.
HK1098752A (en) Process for preparing substituted 8-azabicyclo[3.2.1] octan-3-ols
ZA200702193B (en) 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds